Zydus gets U.S. FDA nod for generic hormone patch
In short
Zydus got U.S. FDA approval for a generic hormone therapy patch. The report says the product may qualify for a 180-day exclusivity period under the CGT pathway, if the law’s conditions are met.
This could help Zydus by giving it a temporary sales advantage. But the report does not say the patch name, launch timing, or how much money it could make.
What the reporting says
Zydus received U.S. FDA approval for a generic version of a hormone therapy patch, according to the available reporting. The product is described as eligible for a 180-day exclusivity period for certain first approved applicants under the CGT pathway, subject to U.S. drug law provisions. The reporting does not name the patch, the timing of launch, or the financial impact.
Why it matters
Zydus received U.S. FDA approval for a generic hormone therapy patch, based on the publisher summary available. The reporting also says the product may be eligible for a 180-day exclusivity period under the CGT pathway, subject to the U.S. Federal Food, Drug, and Cosmetic Act. The immediate commercial effect is unclear because the product name, launch date, and revenue impact are not stated.